Form 4: Director Gary Lyons Exercises NBIX Restricted Stock Units

Neurocrine Biosciences Director Gary Lyons acquired 1,659 shares of common stock through the vesting of restricted stock units.

Summary

• Director Gary A. Lyons acquired 1,659 shares of Neurocrine Biosciences (NBIX) common stock.
• The acquisition resulted from the vesting of restricted stock units (RSUs) granted on May 21, 2025.
• The transaction was executed at a price of $0 per share as part of a standard equity compensation vesting event.
• Following this transaction, the reporting person holds a total of 122,141 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine administrative disclosure of equity compensation vesting with no impact on company operations or strategy.

Positives

• Director maintains a significant equity stake of 122,141 shares, aligning interests with shareholders.
• The majority of shares (116,158) are held in a revocable living trust, indicating long-term holding intent.

Future Outlook

Not applicable as this is a routine disclosure of equity compensation vesting.

Industry Context

StockSavvy.ai notes that routine RSU vesting for board members is a standard corporate governance practice in the biotechnology sector, reflecting typical executive compensation structures rather than a change in market sentiment.

Comparison to Industry Standards

• The transaction follows standard industry practices for director compensation in mid-to-large cap biotech firms.
• The holding structure via a revocable trust is consistent with common wealth management strategies for corporate insiders.

Stakeholder Impact

• Minimal impact on shareholders as this represents the fulfillment of previously disclosed compensation agreements.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Insider Transaction, Form 4, Equity Compensation, Director Ownership